Essay Undergraduate 955 words

Capital Budgeting for R&D Projects: A Critical Review

~5 min read

Abstract

This paper critically evaluates De Reyck and Leus's 2008 article on capital budgeting for research and development projects, published in IIE Transactions. The authors argue that scheduling potential failure events early in a project's timeline can improve its expected net present value (NPV). This review agrees with the underlying premise but challenges the practical utility of the resulting model, noting that its mathematical complexity makes it inaccessible to decision-makers such as CFOs and production managers. The review also highlights an overlooked variable in high-risk R&D industries: risk-sharing through joint ventures and firm-wide capital budgeting, as seen in the pharmaceutical sector.

📝 How to Write This Type of Paper Writing guide — click to expand

▼

What makes this paper effective

The review demonstrates a clear evaluative structure: it first acknowledges merit in the authors' core premise before systematically identifying weaknesses, showing balanced critical thinking.
The writer effectively uses direct quotation from the source article to support a specific critique, letting the authors inadvertently undermine their own claims.
The inclusion of an industry-specific example (pharmaceutical joint ventures) adds analytical depth beyond a simple summary, demonstrating applied knowledge.

Key academic technique demonstrated

This paper demonstrates critical source evaluation — the ability to separate a valid theoretical idea from its practical execution. The writer engages with both the logic of the model and its real-world applicability, maintaining a clear stance throughout while grounding criticism in concrete professional concerns rather than abstract disagreement.

Structure breakdown

The paper opens by summarizing De Reyck and Leus's core argument about NPV and failure scheduling, then validates the underlying premise before shifting to sustained critique of the model's complexity and inaccessibility. A distinct section introduces an overlooked variable — industry-wide risk sharing — before the conclusion calls for a practically usable interface. The argument flows logically from agreement to critique to constructive recommendation.

Introduction to the Capital Budgeting Premise

De Reyck and Leus begin their article with the underlying premise that capital budgeting for research and development projects is inherently different from capital budgeting for normal projects. They contend that the risk of total failure — resulting from failure at any given stage — adds an element of risk not found in conventional projects. Flowing from this assumption is the notion that the constituent activities of a project can be scheduled in such a manner as to increase the expected net present value (NPV) of the project.

Essentially, the NPV of an R&D project is taken to be a weighted average of all probable outcomes and the cash flows that result. Each outcome that results in failure will therefore carry a negative NPV that is included in the overall weighting. What De Reyck and Leus hypothesize is that if the potential failure events driving overall project failure are scheduled as close to the beginning of the project as possible, then the NPV will be improved. That is, if the project is doomed to fail, it is best to structure its development so that failure occurs earlier rather than later, thereby reducing sunk costs prior to that failure.

NPV Weighting and Scheduling Logic

On the surface, this premise makes sense. Firms often evaluate projects on a pass/fail basis, but failure at different stages will naturally produce different degrees of negative NPV. As such, the less money spent before failure occurs, the higher the NPV for the project will be. Scheduling is therefore used as a means to alter one of the variables over which the firm has control — the losses incurred prior to project failure. On the whole, the core argument presented by the authors is sound.

3 Locked Sections · 505 words remaining

Critique of the Model's Complexity and Accessibility · 230 words

"Mathematical complexity limits real-world usefulness for managers"

Missing Variables: Risk Sharing in High-Stakes R&D · 130 words

"Joint ventures and firm-wide risk spreading are overlooked"

Overall Assessment and Recommendations · 145 words

"Model needs a practical interface for decision-makers"

You’re 30% through this paper. Sign up to read the remaining 3 sections.

130,000+ paper examples AI writing assistant Citation generator Cancel anytime

Key Concepts in This Paper

Capital Budgeting Net Present Value R&D Scheduling Project Failure Risk Decision Support Risk Sharing Joint Ventures Pharmaceutical Industry Sunk Costs Model Applicability